Mumbai, May 8 -- Profit before tax (PBT) climbed 36.53% to Rs 64.43 crore in the quarter ended 31st March 2026.

During the quarter, EBITDA increased 31% YoY to Rs 75.09 crore in Q4 FY26 with EBITDA margin improved 34% in Q4 FY26 over Q4 FY25.

During the quarter, the company processed 59 million test, up 29% YoY. Revenue from pathology business jumped 21% YoY.

The company reduced the complaints to 3.1 per million (down 34% YoY) with average turnaround time (ATAT) at 3.43 hours from sample receipt.

The company said that it has epanded test portfolio with advanced allergy testing (over 250 SKUs on the Phadia platform) and entered genomics with a state-of-the-art lab and launch of Non-invasive Pre-Natal Testing (NIPT), alongside a phased ...